<DOC>
	<DOCNO>NCT00171171</DOCNO>
	<brief_summary>Because patient beta-thalassemia unable actively eliminate iron body , toxic eventually lethal level iron accumulate result repeat blood transfusion . This study evaluate efficacy , safety tolerability deferasirox .</brief_summary>
	<brief_title>A Study Long-term Treatment With Deferasirox Patients With Beta-thalassemia Transfusional Hemosiderosis</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Hemosiderosis</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Betathalassemia outpatient transfusional hemosiderosis unable chelate deferoxamine ( DFO ) due DFO contraindicate and/or due document unacceptable toxicity DFO document poor response DFO despite proper compliance , document noncompliance DFO , serum ferritin ≥ 500 ng/ml LIC ≥ 2 mg/Fe/g dw liver Betathalassemia outpatients transfusional hemosiderosis treat deferiprone Means level ALT &gt; 300 U/L Serum creatinine upper limit normal Active hepatitis C chronic hepatitis B receive specific treatment</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Thalassemia ( beta-thal . major )</keyword>
	<keyword>Transfusional hemosiderosis</keyword>
	<keyword>Deferasirox</keyword>
	<keyword>Beta-thalassemia major patient</keyword>
	<keyword>Unable chelate deferoxamine deferiprone</keyword>
</DOC>